Department of Environmental Health Sciences, University Medical Center, Breisacher Str. 115b, D-79106 Freiburg, Germany.
BMC Microbiol. 2012 Mar 27;12:47. doi: 10.1186/1471-2180-12-47.
BACKGROUND: Antibiotic associated diarrhea and Clostridium difficile infection are frequent complications of broad spectrum antibiotic therapy. Probiotic bacteria are used as therapeutic and preventive agents in these disorders, but the exact functional mechanisms and the mode of action are poorly understood. The effects of clindamycin and the probiotic mixture VSL#3 (containing the 8 bacterial strains Streptococcus thermophilus, Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus paracasei and Lactobacillus delbrueckii subsp. Bulgaricus) consecutively or in combination were investigated and compared to controls without therapy using a standardized human fecal microbiota in a computer-controlled in vitro model of large intestine. Microbial metabolites (short chain fatty acids, lactate, branched chain fatty acids, and ammonia) and the intestinal microbiota were analyzed. RESULTS: Compared to controls and combination therapy, short chain fatty acids and lactate, but also ammonia and branched chain fatty acids, were increased under probiotic therapy. The metabolic pattern under combined therapy with antibiotics and probiotics had the most beneficial and consistent effect on intestinal metabolic profiles. The intestinal microbiota showed a decrease in several indigenous bacterial groups under antibiotic therapy, there was no significant recovery of these groups when the antibiotic therapy was followed by administration of probiotics. Simultaneous application of anti- and probiotics had a stabilizing effect on the intestinal microbiota with increased bifidobacteria and lactobacilli. CONCLUSIONS: Administration of VSL#3 parallel with the clindamycin therapy had a beneficial and stabilizing effect on the intestinal metabolic homeostasis by decreasing toxic metabolites and protecting the endogenic microbiota from destruction. Probiotics could be a reasonable strategy in prevention of antibiotic associated disturbances of the intestinal homeostasis and disorders.
背景：广谱抗生素治疗会导致抗生素相关性腹泻和艰难梭菌感染，这是常见的并发症。益生菌被用作这些疾病的治疗和预防药物，但确切的功能机制和作用方式仍不清楚。本研究使用一种标准化的人类粪便微生物群，在计算机控制的大肠体外模型中，连续或联合使用克林霉素和益生菌混合物 VSL#3（含 8 种细菌：嗜热链球菌、短双歧杆菌、长双歧杆菌、婴儿双歧杆菌、嗜酸乳杆菌、植物乳杆菌、干酪乳杆菌和德氏乳杆菌保加利亚亚种），对这些药物的效果进行了研究，并与无治疗的对照组进行了比较。分析了微生物代谢物（短链脂肪酸、乳酸、支链脂肪酸和氨）和肠道微生物群。
结果：与对照组和联合治疗组相比，益生菌治疗组的短链脂肪酸和乳酸以及氨和支链脂肪酸增加。抗生素和益生菌联合治疗的代谢模式对肠道代谢谱有最有益和一致的影响。抗生素治疗会导致肠道内一些土著细菌群减少，当抗生素治疗后给予益生菌时，这些细菌群并没有明显恢复。同时应用抗微生物药物和益生菌对肠道微生物群有稳定作用，双歧杆菌和乳杆菌增加。
结论：在克林霉素治疗的同时给予 VSL#3 具有有益和稳定的作用，可通过减少毒性代谢物并防止内源性微生物群被破坏，从而维持肠道代谢稳态。益生菌可能是预防抗生素相关性肠道稳态紊乱和疾病的合理策略。
Front Cell Infect Microbiol. 2017-5-5
Int J Food Microbiol. 1999-1-12
Cancers (Basel). 2024-9-9
J Fungi (Basel). 2023-1-28
J Fungi (Basel). 2023-1-12
Immune Netw. 2022-11-29
Nutrients. 2011-10-14
Emerg Infect Dis. 2010-4
BMC Microbiol. 2010-1-7
Int J Med Microbiol. 2009-9-23
N Engl J Med. 2008-10-30
Zotero 插件